Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has
the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these
severe cases. Also unknown is the timing and extent of peripheral retinal vascularization
after low-dose bevacizumab compared with the standard dose. The current study will evaluate
whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and
retinal vessels all in zone I.
Phase:
Phase 2
Details
Lead Sponsor:
Jaeb Center for Health Research
Collaborators:
National Eye Institute (NEI) Pediatric Eye Disease Investigator Group